US 11254752
Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11254752 (Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K39/3955